COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes
Gregory JM, Slaughter JC, Duffus SH, et al.
Diabetes Care. 2021;44(2):526-532
Leggi
A healthy lifestyle mitigates the risk of heart disease related to type 2 diabetes: a prospective nested case–control study in a nationwide Swedish twin cohort
Yang R, Xu H, Pedersen NL, et al.
Diabetologia. 2021, 64:530–539
Leggi
Management of diabetes and hyperglycaemia in the hospital
Pasquel FJ, Lansang MC, Dhatariya K, et al.
The Lancet Diabetes & Endocrinology. Pub. online 27 January 2021
Leggi
Comparative effectiveness and safety of sodium–glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults
Patorno E, Pawar A, Bessette LG, et al.
Diabetes Care. 2021 Jan; dc201464
Leggi
Association between diabetes and haematological malignancies: a population-based study
Gong IY, Cheung MC, Read S, et al.
Diabetologia. 2021,64:540–551
Leggi
Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: beyond glycated haemoglobin
Helliwell R, Warnes H, Kietsiriroje N, et al.
Diabet Med. 2021 Jan 27; e14529
Leggi
Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA HF
Inzucchi SE, Docherty KF, Køber L, et al.
Diabetes Care. 2021;44(2):586-594
Leggi
A validated prediction model for end-stage kidney disease in type 1 diabetes
Vistisen D, Andersen GS, Hulman A, et al.
Diabetes Care. 2021 Jan; dc202586
Leggi
Continuous glucose monitoring: a review of the evidence in type 1 and 2 diabetes mellitus
Lin R, Brown F, James S, et al.
Diabet Med. 2021 Jan 26; e14528
Leggi